Home Cart Sign in  
Chemical Structure| 635318-11-5 Chemical Structure| 635318-11-5

Structure of LY404039
CAS No.: 635318-11-5

Chemical Structure| 635318-11-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

LY404039 is an inhibitor for mGluR1 (Ki=149 nM) and mGluR2 (Ki= 92 nM), which can also inhibit dopamine receptor.

Synonyms: pomaglumetad

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of LY404039

CAS No. :635318-11-5
Formula : C7H9NO6S
M.W : 235.21
SMILES Code : O=C([C@]1(N)CS([C@@]2([H])[C@H](C(O)=O)[C@@]12[H])(=O)=O)O
Synonyms :
pomaglumetad
MDL No. :MFCD11974011
InChI Key :AVDUGNCTZRCAHH-MDASVERJSA-N
Pubchem ID :9834591

Safety of LY404039

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of LY404039

GPCR

Isoform Comparison

Biological Activity

Description
LY404039 is a potent and selective mGluR2 and mGluR3 agonist with dissociation constants (Kis) of 149 nM for mGluR2 and 92 nM for mGluR3 in recombinant human receptors, exhibiting over 100-fold selectivity for these receptors over other receptors and transporters. LY404039 has demonstrated both antipsychotic and anxiolytic effects[1].

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01609218 Healthy Volunteer Study Phase 1 Completed - United Kingdom ... More >> For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Leeds, West Yorkshire, United Kingdom, LS2 9LH Less <<
NCT01475136 Hepatic Insufficiency Phase 1 Completed - Germany ... More >> For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Munich, Germany, 81241 Hungary For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Balatonfüred, Hungary, 8230 Less <<
NCT01659177 Healthy Participants Phase 1 Withdrawn(The decision to stop... More >> the trial was based on efficacy results in the overall schizophrenia patient population.) Less << September 2012 Switzerland ... More >> For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Allschwil, Switzerland, CH-4123 Less <<
NCT01637142 Healthy Participants Phase 1 Completed - United Kingdom ... More >> For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Leeds, West Yorkshire, United Kingdom, LS2 9LH Less <<
NCT01440478 Healthy Subjects Phase 1 Completed - United Kingdom ... More >> For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559), Mon - Fri, from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician. Leeds, United Kingdom Less <<
NCT01591330 Healthy Volunteers Phase 1 Completed - United Kingdom ... More >> For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Leeds, West Yorkshire, United Kingdom Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.25mL

0.85mL

0.43mL

21.26mL

4.25mL

2.13mL

42.52mL

8.50mL

4.25mL

Dissolving Methods
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories